1. LBA1 Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study. (15th December 2019) Authors: Herbst, R S; de Marinis, F; Giaccone, G; Reinmuth, N; Vergnenegre, A; Barrios, C H; Morise, M; Felip, E; Andric, Z; Geater, S; Ozguroglu, M; Mocci, S; McCleland, M; Zou, W; Enquist, I; Komatsubara, K; Deng, Y; Kuriki, H; Spigel, D R; Jassem, J Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗